Last reviewed · How we verify

NCT06225076

Efficacy of Stellate Ganglion Block in Dysphagic Patients With Bulbar Palsy After Ischemic Stroke

Withdrawn NA Last updated 5 March 2024
What this trial tests

NA trial testing Comprehensive rehabilitation in Bulbar Palsy. Withdrawn.

Timeline
30 January 2024
Primary endpoint
15 April 2024
30 May 2024

Quick facts

Lead sponsorZeng Changhao
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Start date30 January 2024
Primary completion15 April 2024
Estimated completion30 May 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Zeng Changhao — full company profile →

Who can join

18 and older, any sex, with Bulbar Palsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized controlled study, including dysphagic patients with bulbar palsy after ischemic stroke who were received in the department of rehabilitation medicine in 3 hospitals in China. All patients are randomly allocated to the observation group or the control group. Both groups are provided with comprehensive rehabilitation. Besides, the observation group additionally undergoes the stellate ganglion block. At admission and after 20-day treatment, video fluoroscopic swallowing study, and penetration-aspiration scale, Functional Oral Intake Scale, Flexible laryngoscope are used to assess swallowing function.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Comprehensive rehabilitation

Trials testing the same drug.

Other Zeng Changhao trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06225076.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing